Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin

References

• Kauffman CA. (2006). Clinical efficacy of new antifungal agents. Curr Opin Microbiol, 9:483–488.
   PubMed Web of Science ®Google Scholar
• Khan MA, Faisal SM, Mohammad O. (2006). Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model. J Drug Target, 14:233–241.
   PubMed Web of Science ®Google Scholar
• Pace HR, Schantz SI. (1956). Nystatin (mycostatin) in the treatment of monilial and nonmonilial vaginitis. J Am Med Assoc, 162:268–271.
   PubMed Web of Science ®Google Scholar
• Ng AW, Wasan KM, Lopez-Berestein G. (2003). Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci, 6:67–83.
   PubMed Web of Science ®Google Scholar
• Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G. (1987). Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother, 31:1901–1903.
   PubMed Web of Science ®Google Scholar
• Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E. (1997). Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother, 41:2238–2243.
   PubMed Web of Science ®Google Scholar
• Frokjaer S, Hjorth EL, Worts O. Stability testing of liposomes during storage. In Liposome Technology: Preparation of Liposomes, 1st edn., Gregoriadis, G. (ed.), Vol. 1, (1984), CRC Press Inc, Boca Raton, FL, pp. 235–245.
   Google Scholar
• Arien A, Dupuy B. (1997). Encapsulation of calcitonin in liposomes depends on the vesicle preparation method. J Microencapsul, 14:753–760.
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm, 59:485–490.
   PubMed Web of Science ®Google Scholar
• Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. (1985). The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol, 37:237–242.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Vyas SP. (1998). Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm, 172:33–70.
   Web of Science ®Google Scholar
• Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci, 58:1–55.
   Web of Science ®Google Scholar
• Arora R, Jain CP. (2007). Advances in niosome as a drug carrier: A review. Asian J Pharm, 1: 29–39.
   Google Scholar
• Junyaprasert VB, Teeranachaideekul V, Supaperm T. (2008). Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharmscitech, 9:851–859.
   PubMed Web of Science ®Google Scholar
• Palozza P, Muzzalupo R, Trombino S, Valdannini A, Picci N. (2006). Solubilization and stabilization of beta-carotene in niosomes: delivery to cultured cells. Chem Phys Lipids, 139:32–42.
   PubMed Web of Science ®Google Scholar
• Azeem A, Anwer MK, Talegaonkar S. (2009). Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target, 17:671–689.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 13:238–252.
   PubMed Web of Science ®Google Scholar
• Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. (1985). The preparation and properties of niosomes–non-ionic surfactant vesicles. J Pharm Pharmacol, 37:863–868.
   PubMed Web of Science ®Google Scholar
• Khan MA, Firoz A, Jabeen R, Mohammad O. (2004). Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice. J Drug Target, 12:425–433.
   PubMed Web of Science ®Google Scholar
• Khan MA, Nasti TH, Saima K, Mallick AI, Firoz A, Wajahul H et al. (2004). Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol Med Microbiol, 41:249–258.
   PubMed Web of Science ®Google Scholar
• Khan MA, Syed FM, Nasti HT, Saima Dagger K, Haq W, Shehbaz A et al. (2003). Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. j Drug Target, 11:93–99.
   PubMed Web of Science ®Google Scholar
• Moribe K, Maruyama K, Iwatsuru M. (2000). Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes. Int J Pharm, 201:37–49.
   PubMed Web of Science ®Google Scholar
• Moribe K, Maruyama K, Iwatsuru M. (1999). Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives. Int J Pharm, 188:193–202.
   PubMed Web of Science ®Google Scholar
• Nasti TH, Khan MA, Owais M. (2006). Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model. J Antimicrob Chemother, 57:349–352.
   PubMed Web of Science ®Google Scholar
• Cassidy SM, Strobel FW, Wasan KM. (1998). Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins. Antimicrob Agents Chemother, 42:1878–1888.
   PubMed Web of Science ®Google Scholar
• Wasan KM, Ramaswamy M, Cassidy SM, Kazemi M, Strobel FW, Thies RL. (1997). Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother, 41:1871–1875.
   PubMed Web of Science ®Google Scholar
• Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. (1987). Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother, 31:1897–1900.
   PubMed Web of Science ®Google Scholar
• Hashim F, El-Ridy M, Nasr M, Abdallah Y. (2010). Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv, 17:282–287.
   PubMed Web of Science ®Google Scholar
• El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S. (2007). Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm, 330:82–88.
   PubMed Web of Science ®Google Scholar
• Mokhtar M, Sammour OA, Hammad MA, Megrab NA. (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm, 361:104–111.
   PubMed Web of Science ®Google Scholar
• Nystatin. In: British Pharmacopoeia, vol. II, (2007), pp. 1497–1498.
   Google Scholar
• Hong M, Zhu S, Jiang Y, Tang G, Pei Y. (2009). Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release, 133:96–102.
   PubMed Web of Science ®Google Scholar
• Di Marzio L, Marianecci C, Petrone M, Rinaldi F, Carafa M. (2011). Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20. Colloids Surf B Biointerfaces, 82:18–24.
   PubMed Web of Science ®Google Scholar
• Marianecci C, Paolino D, Celia C, Fresta M, Carafa M, Alhaique F. (2010). Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release, 147:127–135.
   PubMed Web of Science ®Google Scholar
• Carafa M, Santucci E, Lucania G. (2002). Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm, 231:21–32.
   PubMed Web of Science ®Google Scholar
• Sentjurc M, Vrhovnik K, Kristl J. (1999). Liposomes as a topical delivery system: the role of size on transport studied by the EPR imaging method. J Control Release, 59:87–97.
   PubMed Web of Science ®Google Scholar
• Centis V, Vermette P. (2008). Physico-chemical properties and cytotoxicity assessment of PEG-modified liposomes containing human hemoglobin. Colloids Surf B Biointerfaces, 65:239–246.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D. (1978). Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol, 27:21–27.
   PubMed Web of Science ®Google Scholar
• El-Ridy MS, Kassem M, Akbarieh M, Tawashi R. (1988). The effect of surface charge of liposomes on aggregation in the buccal cavity. In: Proceedings 15th Int. Symp. Control. Rel. Bioact. Mater. Basel, Switzerland.
   Google Scholar
• Parisi AN, Antoine AD. (1975). Characterization of Bacillus pumilus E601 spores after single sublethal gamma irradiation treatments. Appl Microbiol, 29:34–39.
   PubMedGoogle Scholar
• Gamble M. (1996). The hematosylins and eosin. In: Bancroft JD, Stevens A, Turner DR (ed.), Theory and Practice of Histological Techniques, 4th edn. Churchill Livingstone, New York, Edinburgh, London, Madrid, Melbourne, San Francisco, Tokyo, pp. 99–112.
   Google Scholar
• Groll AH, Mickiene D, Werner K, Petraitiene R, Petraitis V, Calendario M et al. (2000). Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob Agents Chemother, 44:950–957.
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Werner K, Piscitelli SC, Walsh TJ. (1999). High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. J Chromatogr B Biomed Sci Appl, 735:51–62.
   PubMedGoogle Scholar
• Groll AH, Mickiene D, Petraitis V, Petraitiene R, Alfaro RM, King C et al. (2003). Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob Agents Chemother, 47:3917–3925.
   PubMed Web of Science ®Google Scholar
• Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I et al. (2002). Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother, 46:2442–2449.
   PubMed Web of Science ®Google Scholar
• Denning DW, Warn P. (1999). Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother, 43:2592–2599.
   PubMed Web of Science ®Google Scholar
• Shi B, Fang C, Pei Y. (2006). Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci, 95:1873–1887.
   PubMed Web of Science ®Google Scholar
• Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci, 251:360–365.
   PubMed Web of Science ®Google Scholar
• Abdelbary G, El-Gendy N. (2008). Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS Pharmscitech, 9:740–747.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Sankar V. (2010). Formulation and optimization of Zidovudine niosomes. AAPS Pharmscitech, 11:1119–1127.
   PubMed Web of Science ®Google Scholar
• Gianasi E, Cociancich F, Uchegbu IF, Florence AT, Duncan R. (1997). Pharmaceutical and biological characterization of a doxorubicin polymer conjugate (PK1) entrapped in sorbitan monostearate Span 60 niosomes. Int J Pharm, 148:139–148.
   Web of Science ®Google Scholar
• Jain S, Umamaheswari B, Bhadra D, Jain NK. (2004). Ethosomes: a novel carrier for enhanced transdermal delivery of an anti-HIV agent. Indian J Pharm Sci, 66:72–81.
   Google Scholar
• Hac-Wydro K, Dynarowicz-Latka P. (2006). Nystatin in Langmuir monolayers at the air/water interface. Colloids Surf B Biointerfaces, 53:64–71.
   PubMed Web of Science ®Google Scholar
• Hao YM, Li K. (2011). Entrapment and release difference resulting from hydrogen bonding interactions in niosome. Int J Pharm, 403:245–253.
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. (2004). Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm, 285:23–34.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nakano K, Ishikawa C, Yamamoto M, Matsumoto Y, Iwahara M, Furusaki S, Ueoka R. (2002). Enhanced inhibitory effects of extracts from Ginkgo biloba L. leaves encapsulated in hybrid liposomes on the growth of tumor cells in vitro. Biochem Eng J, 12:125–130.
   Web of Science ®Google Scholar
• Nasr M, Mansour S, Mortada ND, Elshamy AA. (2008). Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J Microencapsul, 25:499–512.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm, 244:73–80.
   PubMedGoogle Scholar
• Yoshioka T, Sternberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm, 105:1–6.
   Web of Science ®Google Scholar
• Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH et al. (2009). Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm, 377:1–8.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Wongtrakulc P, Manosroia J, Sakaid H, Sugawarad F, Yuasad M, Abed M. (2003). Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf. B: Biointerfaces, 30:129–138.
   Web of Science ®Google Scholar
• RajaNaresh RA, Pillai GK, Udupa N, Chandrashekar G. (1994). Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol, 26:46–48.
   Google Scholar
• Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm, 234:237–248.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306:71–82.
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. (2010). Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, 99:2049–2060.
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Chauhan S, Lawrence SM, Barlow DJ. (1996). The formation, characterization and stability of non-ionic surfactant vesicles. STP Pharm Sci, 6:49–60.
   Google Scholar
• Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. (2003). Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv, 10:251–262.
   PubMed Web of Science ®Google Scholar
• Fresta M, Puglisi G. (1997). Corticosteroid dermal delivery with skin-lipid liposomes. J Control Release, 44:141–151.
   Web of Science ®Google Scholar
• El Maghraby GM, Campbell M, Finnin BC. (2005). Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes. Int J Pharm, 305:90–104.
   PubMedGoogle Scholar
• Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R et al. (2010). Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul, 27:618–627.
   PubMed Web of Science ®Google Scholar
• Seras-Cansel A, Ollivon M, Lesieur S. (1996). Generation of non-ionic monoalkyl amphiphile-cholesterol vesicles: Evidence of membranen impermeability to octyl glycoside. STP Pharm Sci, 6:12–20.
   Google Scholar
• Attia IA, El-Gizawy SA, Fouda MA, Donia AM. (2007). Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS Pharmscitech, 8:E106.
   PubMed Web of Science ®Google Scholar
• Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm, 328:130–141.
   PubMed Web of Science ®Google Scholar
• Khazaeli P, Pardakhty A, Shoorabi H. (2007). Caffeine-loaded niosomes: characterization and in vitro release studies. Drug Deliv, 14:447–452.
   PubMed Web of Science ®Google Scholar
• Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. (2006). Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm, 323:1–10.
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. (1999). Niosomal delivery of 5-fluorouracil. J Microencapsul, 16:731–740.
   PubMed Web of Science ®Google Scholar
• Perrett S, Golding M, Williams WP. (1991). A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J Pharm Pharmacol, 43:154–161.
   PubMed Web of Science ®Google Scholar
• Hal DAV, Bouwstra JA, Rensen AV, Jeremiasse E, Vringer TD, Junginger HE. (1996). Preparation and characterization of non-ionic surfactant vesicles. J Colloid Interface Sci, 178:263–273.
   Web of Science ®Google Scholar
• Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR. (1998). Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm, 160:51–59.
   Web of Science ®Google Scholar
• Fang JY, Hong CT, Chiu WT, Wang YY. (2001). Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm, 219:61–72.
   PubMed Web of Science ®Google Scholar
• Vora B, KhopadeAJ Jain, NK. (1998). Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release, 54:149–165.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G, Storm G. (2005). Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia, 7:118–127.
   PubMed Web of Science ®Google Scholar
• Barakat HS, Darwish IA, El-Khordagui LK, Khalafallah NM. (2009). Development of naftifine hydrochloride alcohol-free niosome gel. Drug Dev Ind Pharm, 35:631–637.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm, 26:217–222.
   PubMed Web of Science ®Google Scholar
• Weiner N, Williams N, Birch G, Ramachandran C, Shipman C Jr, Flynn G. (1989). Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother, 33:1217–1221.
   PubMed Web of Science ®Google Scholar
• Betageri GV, Parsons DL. (1992). Drug encapsulation and release from multilamellar and unilamellar liposomes. Int J Pharm, 81:235–241.
   Web of Science ®Google Scholar
• Rogerson A, Cummings J, Florence AT. (1987). Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul, 4:321–328.
   PubMed Web of Science ®Google Scholar
• Cocera M, Lopez O, Coderch L, Parra JL, de la Maza A. (2003). Permeability investigations of phospholipids liposomes by adding cholesterol. Colloid Surfaces A Physicochem Eng Aspects, 221:9–17.
   Web of Science ®Google Scholar
• Hofland HE, Bouwstra JA, Verhoef JC, Buckton G, Chowdry BZ, Ponec M et al. (1992). Safety aspects of non-ionic surfactant vesicles: a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J Pharm Pharmacol, 44:287–294.
   PubMed Web of Science ®Google Scholar
• Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G. (1994). Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci, 83:1006–1010.
   PubMed Web of Science ®Google Scholar
• Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA et al. (1994). Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother, 38:713–718.
   PubMed Web of Science ®Google Scholar
• Dupont B. (2002). Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother, 49 Suppl 1:31–36.
   PubMed Web of Science ®Google Scholar
• Kirsh R, Poste G. (1986). Liposome targeting to macrophages: opportunities for treatment of infectious diseases. Adv Exp Med Biol, 202:171–184.
   PubMedGoogle Scholar